Glycogen synthase kinase‐3β participates in acquired resistance to gemcitabine in pancreatic cancer

Acquisition of resistance to gemcitabine is a challenging clinical and biological hallmark property of refractory pancreatic cancer. Here, we investigated whether glycogen synthase kinase (GSK)‐3β, an emerging therapeutic target in various cancer types, is mechanistically involved in acquired resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Uehara, Masahiro, Domoto, Takahiro, Takenaka, Satoshi, Bolidong, Dilireba, Takeuchi, Osamu, Miyashita, Tomoharu, Minamoto, Toshinari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734171/
https://www.ncbi.nlm.nih.gov/pubmed/32986894
http://dx.doi.org/10.1111/cas.14668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734171/
https://www.ncbi.nlm.nih.gov/pubmed/32986894
http://dx.doi.org/10.1111/cas.14668

Ejemplares similares